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Abstract
Introduction: Although both statins and fibrates have been found to reduce monocyte cytokine release, no study has investigated whether 
the effect of hypolipidaemic agents depends on age.
Materials and methods: This study retrospectively analysed the results of 65 patients with type 2 diabetes and atherogenic dyslipidae-
mia, complying with lifestyle intervention, and receiving metformin. These patients were then treated with simvastatin (40 mg daily), 
micronized fenofibrate (200 mg daily), or simvastatin plus fenofibrate. Tumour necrosis factor-a (TNF-a), inteleukin-1b, interleukin-6, and 
monocyte chemoattractant protein-1 (MCP-1) release, as well as circulating levels of high-sensitivity C-reactive protein (hsCRP), were 
determined separately for patients aged between 20 and 50 years and between 51 and 75 years before the study and after 12 weeks of 
hypolipidaemic treatment.
Results: Older adults were characterised by higher monocyte release of TNF-a and interleukin-6, as well as higher circulating levels of 
hsCRP, than the younger subjects. The decrease in monocyte release of all investigated cytokines and in plasma hsCRP was similar in 
both age groups. In turn, the effect of fenofibrate, alone or in combination with simvastatin, on TNF-a, interleukin-6, and hsCRP, but not 
on interleukin-1b and MCP-1, was stronger in patients aged between 50 and 75 years, and correlated with an improvement in insulin 
sensitivity only in this age group.
Conclusions: Our results suggest that age may partially determine monocyte-suppressing and systemic anti-inflammatory effects of 
fenofibrate. (Endokrynol Pol 2016; 67 (2): 190–196)
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Streszczenie
Wstęp: Chociaż zarówno statyny, jak i fibraty wydają się zmniejszać wydzielanie cytokin prozapalnych, jak dotąd nie badano, czy wpływ 
tych leków na funkcję sekrecyjną monocytów zmienia się z wiekiem pacjenta.
Materiał i metody: Badanie stanowiło retrospektywną analizę wyników 65 chorych na cukrzycę typu 2 i dyslipidemię aterogenną, 
przestrzegających zaleceń zmiany stylu życia i leczonych metforminą. Pacjenci ci byli następnie leczeni simwastatyną (40 mg dziennie), 
fenofibratem (200 mg dziennie) lub terapią skojarzoną oboma lekami (w powyższych dawkach). Ocenę wydzielania czynnika martwicy 
nowotworów a (TNF-a), inteleukiny-1b, interleukiny 6 oraz białka chemotaktycznego dla monocytów-1 (MCP-1) przez aktywowane 
monocyty, jak również ocenę stężenia w osoczu białka C-reaktywnego (hsCRP) porównywano pomiędzy chorymi w wieku 20–50 lat 
oraz 51–75 lat w warunkach wyjściowych i po 12 tygodniach stosowania terapii hipolipemicznej.
Wyniki: Starsza grupa wiekowa charakteryzowała się wyższym wydzielaniem TNF-a i interleukiny-6, jak również wyższym stężeniem 
hsCRP. U chorych otrzymujących simwastatynę hamujący wpływ tego leku na sekrecję cytokin prozapalnych i stężenie hsCRP był podobny 
w obu przedziałach wiekowych. Z kolei wpływ fenofibratu oraz terapii skojarzonej na wydzielanie TNF-a i interleukiny-6 oraz stężenie 
hsCRP, ale nie na sekrecję inteleukiny-1b i MCP-1 był bardziej wyrażony w starszej grupie wiekowej i jedynie w tej grupie korelował 
z poprawą wrażliwości na insulinę.
Wnioski: Wyniki badania sugerują, że wiek pacjenta może odgrywać rolę dla siły działania fenofibratu na funkcję sekrecyjną monocytów 
u chorych z cukrzycą typu 2 i dyslipidemią aterogenną. (Endokrynol Pol 2016; 67 (2): 190–196)
Słowa kluczowe: wiek; simwastatyna; fenofibrat; dyslipidemia aterogenna; monocyty; cytokiny 
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inflammatory, antioxidant, and antithrombotic proper-
ties, and improve endothelial function [21–24] and both 
lipid- and non-lipid-related mechanisms participating 
in the reduction of cardiovascular endpoints in statin 
[8, 9] and some fibrate trials [19, 20]. Interestingly, in 
one of our previous studies, simvastatin and fenofi-
brate reduced monocyte cytokine release but this ef-
fect was not stronger if both drugs were administered 
together [18]. This effect on the secretory function of 
cells abundantly present in atherosclerotic lesions and 
playing a role in atherogenesis [25, 26] is in line with the 
results of the Action to Control Cardiovascular Risk in 
Diabetes Lipid trial (ACCORD) [27]. This large clinical 
trial revealed that a simvastatin-fenofibrate combina-
tion was equipotent to simvastatin alone in decreasing 
cardiovascular and cerebrovascular risk in middle-aged 
and elderly subjects with type 2 diabetes and coro-
nary artery disease or increased cardiovascular risk. 
Moreover, in our recent study, the effect of simvastatin/ 
/fenofibrate combination therapy on monocyte release 
of interleukin-6 and MCP-1 was more pronounced in 
the male population [28]. This finding is also in agree-
ment with the results of ACCORD [27], in which statin/ 
/fibrate combination therapy was superior to statin 
alone in men but not in women.
To the best of our knowledge, no previous study 
has investigated whether the effect of hypolipidaemic 
agents on monocyte secretory function and systemic in-
flammation is determined by age. The aim of our study 
was to compare the effects of simvastatin, fenofibrate, 
and simvastatin/fenofibrate combination therapy on 
monocyte cytokine release and low-grade inflammation 
between two different aged populations of patients 
with type 2 diabetes mellitus and dyslipidaemia.
Material and methods
Our study was a retrospective analysis of data of 
65 patients (20–75 years old) with type 2 diabetes (fasting 
plasma glucose at least 126 mg/dL or plasma glucose 
concentration two hours after a glucose load of at 
least 200 mg/dL) and atherogenic dyslipidaemia. To 
be admitted to the study they (a) had be treated with 
metformin (1.7–2.55 g daily), (b) had to comply with 
the lifestyle modification (total fat intake < 30% of 
total energy intake, saturated fat intake < 7% of energy 
consumed, cholesterol intake < 200 mg per day, an 
increase in fibre intake to 15 g per 1,000 kcal, moderate 
to vigorous exercise for at least 30 minutes per day) for 
at least 12 weeks before the beginning of the study; 
and (c) were required to have HDL cholesterol levels 
below 40 mg/dL in men and 50 mg/dL in women, and 
triglycerides at least 150 mg/dL. Of 65 analysed patients, 
46 individuals participated in the previous study [18]. 
Abbreviations 
ACCORD Lipid — the Action to Control Cardiovascular 
Risk in Diabetes Lipid
CRP — C-reactive protein
HDL — high-density lipoprotein
HMG-CoA — 3-hydroxy-3-methylglutaryl coenzyme A
HOMA-IR — the homeostatic model assessment of 
insulin resistance ratio
hsCRP — high-sensitivity C-reactive protein
LDL — low-density lipoprotein
PPAR-a — peroxisome proliferator-activated receptor-a
TNF-a — tumour necrosis factor-a
Introduction
The prevalence of diabetes and lipid metabolism 
abnormalities increases with age, and cardiovascular 
disease, being a frequent complication of metabolic 
disorders, is a leading cause of death of older adults 
in developed countries [1, 2]. One of the possible 
mechanisms explaining the relationship between age 
and these disorders is a proinflammatory state. Aging 
is characterised by a two- to four-fold increase in cir-
culating levels of inflammatory mediators, particularly 
TNF-a, interleukin-6, and interleukin-1 [3]. All these 
cytokines exert a multi-directional proatherogenic ef-
fect, and their increased production may contribute to 
the development and progression of atherosclerosis [4, 
5]. Aging is also associated with higher plasma levels of 
C-reactive protein (CRP), regarded as a sensitive marker 
of systemic inflammation of high prognostic value in 
the prediction of cardiovascular risk [6, 7]. 
Although large clinical trials have shown that 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors reduced cardiovascular morbid-
ity and mortality [8, 9] the percentage of older adults 
included in these studies was small [10–12]. There is, 
however, some evidence, based on subgroup analyses, 
that statin therapy in elderly patients is as effective 
as in younger patients [10, 12]. Despite these obvious 
benefits, statin therapy seems to be associated with 
a slightly increased risk of development of diabetes [13, 
14]. An improvement in glucose homeostasis was, in 
turn, induced by peroxisome proliferator-activated 
receptor-a (PPARa) activators (fibrates) [15–18], but 
the favourable effect of this group of hypolipidaemic 
agents on cardiovascular morbidity and mortality was 
observed only in some studies [19, 20]. Moreover, no 
large clinical study has investigated the relationship 
between age and clinical effectiveness of PPARa activa-
tors or included only older adults. 
As well as lowering plasma lipids, both HMG-CoA 
reductase inhibitors and PPAR-a activators exert anti-
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However, because they met all inclusion criteria and 
the study protocol that they followed was exactly the 
same as that required in the present study, their results 
were included in our analysis. In turn, the results of 
53 patients were used by our research group in an analysis 
investigating whether sex differences determine the 
strength of monocyte-suppressing and systemic anti-
inflammatory effects of simvastatin, fenofibrate, and 
simvastatin/fenofibrate combination therapy in type 2 
diabetic patients with atherogenic dyslipidaemia [28].
The study excluded patients with type 1 diabetes, 
other forms of dyslipidaemias, autoimmune disorders, 
any acute and chronic inflammatory processes, unstable 
coronary artery disease, myocardial infarction or stroke 
within six months preceding the study, untreated stage 
2 or 3 hypertension (according to the 2003 European 
Society of Hypertension-European Society of Cardiol-
ogy guidelines), symptomatic congestive heart failure, 
body mass index above 35 kg/m2, impaired renal or 
hepatic function, and malabsorption syndromes. In 
most patients, type 1 diabetes was excluded based on 
personal history and clinical picture. In case of any 
doubts we measured circulating levels of C-peptide, 
and titres of glutamic acid decarboxylase, islet cell, and 
insulinoma-associated-2 autoantibodies. No patient was 
allowed to receive antidiabetic (with the exception of 
metformin) or hypolipidaemic agents, drugs interacting 
with statins or fibrates, as well as drugs known to affect 
inflammatory processes in the vascular wall (including 
non-steroid anti-inflammatory drugs, angiotensin-con-
verting enzyme inhibitors, and angiotensin II receptor 
blockers) within three months before the study onset. 
The study protocol was approved by the local ethics 
committee. Informed consent was obtained from all 
enrolled participants. During the study, all participants, 
as well as complying with the lifestyle modification and 
metformin treatment (at the same dose as before the 
study) were treated with constant doses of simvastatin 
(40 mg daily), micronised fenofibrate (200 mg daily), 
or simvastatin (40 mg daily) plus fenofibrate (200 mg 
daily). Both drugs were administered once daily for 
12 weeks. Based on age, each treatment group was divided 
into two subgroups: patients aged between 20 and 
50 years and patients aged between 51 and 75 years. Com- 
pliance was monitored during each visit by tablet count.
Venous blood samples were collected from patients 
twice, at the beginning and at the end of the treatment 
period. Blood was drawn in the morning between 
8.00 and 9.00 a.m. to avoid circadian variations in the 
parameters studied after an overnight fast. All assays 
were made in duplicate to minimise analytical errors. 
Total cholesterol, HDL cholesterol, LDL cholesterol, 
and triglycerides were measured colourimetrically 
using commercially available kits obtained from bi-
oMerieux (France). Circulating glucose levels were 
analysed by a glucose oxidase method (Beckman, Palo 
Alto, CA, USA), and plasma insulin concentration was 
measured with a commercial radioimmunoassay kit 
(Linco Research Inc., St Charles, MO, USA). To avoid 
mistakes resulting from the Friedewald formula, LDL 
cholesterol was determined directly. Insulin resistance 
was assessed through the homeostatic model assess-
ment — insulin resistance index (HOMA-IR) using 
the following equation: [fasting glucose (mg/dL) × 
fasting insulin (μU/mL)/405]. Glycated haemoglobin 
was measured by DCA 2000 (Bayer Ames Technicon, 
Tarrytown, NY, USA) standardised to Diabetes Control 
and Complications Trial standards. Plasma levels of CRP 
were determined using a high-sensitivity monoclonal 
antibody assay (hsCRP) (MP Biomedicals, Orangeburg, 
NY, USA). Lipopolysaccharide-stimulated monocytes 
were cultured in triplicate, as previously described [29, 
30]. Monocyte release of TNF-a, inteleukin-1b, interleu-
kin-6, and MCP-1 was measured using commercial en-
zyme-linked immunosorbent assay kits (R&D Systems, 
McKinley Place N.E. Minneapolis, MN), according to 
the manufacturer’s instructions. The minimum detect-
able levels for the assessed variables were: 0.1 ng/mL 
(hsCRP), 4.4 pg/mL (TNF-a), 1.0 pg/mL (inteleukin-1b), 
3.8 pg/mL (interleukin-6), and 5.0 pg/mL (MCP-1). Intra- 
and interassay coefficients of variation were less than 
5.8 and 8.6%, respectively.
The Kolmogorov-Smirnov test was used to evaluate 
data for underlying assumptions of normality. Values 
for HOMA-IR, triglycerides, hsCRP, and cytokines were 
natural log transformed to yield a normal distribution 
for statistical analyses. Student’s t-test for independent 
samples was used to determine whether any statisti-
cally significant difference existed between both age 
populations, while Student’s paired t test was used to 
investigate the significance of change within the same 
group. The chi2 test was used for categorical data, and 
Kendall’s tau test was used to determine the significance 
of each correlation. A value of p < 0.05 was considered 
statistically significant.
Results
To obtain sex-, weight-, and plasma lipid-matched 
populations of younger and older adults, we analysed 
the samples obtained from 65 patients, treated with 
simvastatin (n = 22), fenofibrate (n = 21) or simvastatin/ 
/fenofibrate combination therapy (n = 22), and only data 
of these patients were included in the final analyses. At 
baseline, both groups were comparable with respect to 
sex, smoking habits, blood pressure, body mass index, 
plasma lipids, plasma glucose, and glycated haemo-
globin (Table I). The older adults were characterised 
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by higher circulating levels of hsCRP. Compared to 
monocytes of younger patients, lipopolysaccharide-
stimulated monocytes of patients aged 50–75 years 
released larger amounts of TNF-a and inteleukin-6, 
but not of interleukin-1b and MCP-1. 
Simvastatin, fenofibrate, and simvastatin/fenofibrate 
combination therapy were well tolerated and all pa-
tients completed the study protocol. All safety param-
eters (aminotransferases, creatine kinase, creatinine, 
and blood morphology) remained within normal limits.
Expectedly, simvastatin, fenofibrate, and simvas-
tatin/fenofibrate combination therapy administered 
to patients with type 2 diabetes and atherogenic 
dyslipidaemia complying with lifestyle intervention 
and treated with metformin decreased total choles-
terol, LDL cholesterol, and triglycerides and increased 
HDL cholesterol (Table II). Moreover, fenofibrate and 
simvastatin/fenofibrate combination therapy reduced 
HOMA-IR and fasting glucose. The effect of fenofibrate 
alone or in combination with simvastatin on HOMA-IR 
was stronger in the older than in the younger adults. In 
both age groups the effect of fenofibrate on HOMA-IR, 
glucose, glycated haemoglobin, and triglycerides was 
stronger, while the effect on total and LDL cholesterol 
was weaker than that of simvastatin (Table II).
Table I. Baseline characteristics of the participants
Tabela I. Wyjściowa charakterystyka pacjentów
Younger  
adults1 
(n = 30)
Older  
adults2 
(n = 35)
Number of patients 30 35
Age (years; mean [SD]) 41 (4) 61 (5)b
Smokers (%) 20 20
Body mass index [kg/m2; mean (SD)] 27.8 (2.5) 28.8 (3.0)
Grade 1 hypertension (%) 73 69
Total cholesterol [mg/dL; mean (SD)] 215 (20) 220 (21)
LDL cholesterol [mg/dL; mean (SD)] 131 (14) 135 (17)
HDL cholesterol [mg/dL; mean (SD)] 35 (4) 34 (4)
Triglycerides [mg/dL; mean (SD)] 230 (39) 245 (40)
Glucose [mg/dL; mean (SD)] 144 (12) 149 (13)
HOMA-IR [mean (SD)] 9.6 (1.1) 10.7 (1.4)
Glycated haemoglobin (%; mean [SD]) 7.1 (0.6) 7.4 (0.5)
hsCRP [mg/L; mean (SD)] 3.1 (0.7) 3.8 (0.7)a
TNF-a [pg/mL; mean (SD)] 1620 (265) 1925 (292)a
Interleukin-1b [pg/mL; mean (SD)] 139 (28) 153 (30)
Interleukin-6 [ng/mL; mean (SD)] 9.1 (2.6) 12.1 (2.9)a
MCP-1 [ng/mL; mean (SD)] 19.8 (4.1) 22.5 (3.9)
120–50 years old; 251–75 years old; ap < 0.05, bp < 0.001 vs. younger adults
Table II. The effect of 12-week treatment with simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy on 
plasma lipids, glucose metabolism markers, low-grade inflammation, and monocyte release of the investigated cytokines in 
different age groups of patients with type 2 diabetes and atherogenic dyslipidaemia
Tabela II. Wpływ dwunastotygodniowego stosowania simwastatyny, fenofibratu oraz terapii skojarzonej na stężenie lipidów, 
markery gospodarki węglowodanowej, układowy stan zapalny oraz wydzielanie przez monocyty cytokin prozapalnych 
u chorych na cukrzycę typu 2 oraz dyslipidemię aterogenną
Simvastatin Fenofibrate Combination therapy
Younger adults1 
(n = 10)
Older adults2 
(n = 12)
Younger adults1 
(n = 10)
Older adults2 
(n = 11)
Younger adults1 
(n = 10)
Older adults2 
(n = 12)
DTotal cholesterol [mg/dL; mean (SD)] –57 (20)c, i –51 (18)c, i –24 (8)a –26 (9)a –63 (16)c, i –70 (12)c, i
DLDL cholesterol [mg/dL; mean (SD)] –44 (16)c, h –41 (13)c, h –22 (7)a –20 (8)a –46 (14)c, i –48 (15)c, i
DHDL cholesterol [mg/dL; mean (SD)] 8 (4)a 6 (4)a 10 (5)b 8 (4)b 12 (5)c, d 13 (5)c, d
DTriglycerides (mg/dL; mean [SD]) –39 (21)a –35 (20)a –61 (20)b, d –56 (16)b, d –82 (18)c, f, g –80 (15)c, f, g
DGlucose [mg/dL; mean (SD)] –5 (6) –4 (5) –12 (6)a, d –14 (7)a, d –12 (7)a, d –13 (6)a, d
DHOMA-IR [mean (SD)] 0.1 (0.8) 0.3 (0.8) –2.3 (0.8)b, e –3.5 (1.1)b, e, j –2.5 (0.9)a, f –4.1 (1.0)c, f, j
DGlycated haemoglobin (%; mean [SD]) 0.1 (0.3) 0.2 (0.2) –0.5 (0.2)a, d –0.7 (0.3)a, d –0.8 (0.3)b, d –0.6 (0.4)b, d
DhsCRP [mg/L; mean (SD)] –1.4 (0.6)b –1.4 (0.7)b –1.1 (0.4)a –1.7 (0.5)a –1.7 (0.5)b, g –2.3 (0.6)c, d, g, j
DTNF-a [pg/mL; mean (SD)] –613 (180)b –665 (245)b –440 (254) –751 (208)b, j –702 (202)c, g –960 (189)c, d, g, j
DInterleukin-1b [pg/mL; mean (SD)] –59 (18)b –57 (16)b –56 (12)b –64 (16)b –55 (14)c –65 (18)c
DInterleukin-6 [ng/mL; mean (SD)] –3.0 (1.2)a –3.5 (1.4)a –2.5 (1.0) –3.9 (1.2)b, j –2.9 (0.9)a –5.0 (1.5)c, d, g, j
DMCP-1 [ng/mL; mean (SD)] –6.0 (1.1)b –6.3 (1.4)b –6.0 (1.5)b –6.2 (1.8)b –6.5 (1.7)b –8.0 (2.3)c
120–50 years old; 251–75 years old.; ap < 0.05; bp < 0.01; cp < 0.001 post-treatment vs. baseline value; dp < 0.05; ep < 0.01; fp < 0.001 vs. the effect of simvastatin 
in the same age group; gp < 0.05; hp < 0.01; ip < 0.001 vs. the effect of fenofibrate in the same age group; jp < 0.05 vs. the effect of the same treatment option in 
younger patients
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Simvastatin reduced monocyte release of TNF-a, 
inteleukin-1b, interleukin-6, and MCP-1, and decreased 
plasma hsCRP levels, and the strength of this action 
was similar in both age groups (Table II). Fenofibrate 
administered alone reduced monocyte release of 
interleukin-1b and MCP-1 in both younger and older 
patients. Although fenofibrate decreased TNF-a and 
inteleukin-6, this effect was statistically significant 
only in patients aged between 51 and 75 years and its 
strength differed between both age populations. It also 
reduced plasma hsCRP in both age groups, but this 
effect was more pronounced in the older age group 
(Table II). As this table also shows, the strongest effect 
on plasma lipids, hsCRP, and TNF-a and inteleukin-6 
release was observed in older adults receiving both 
simvastatin and fenofibrate. Simvastatin/fenofibrate 
combination therapy decreased monocyte release of all 
investigated proinflammatory cytokines and circulat-
ing hsCRP levels in both age populations. However, its 
effect on TNF-a, inteleukin-1b, and hsCRP was more 
pronounced in patients aged between 51 and 75 years 
than between 20 and 50 years (Table II).
Correlations between the assessed variables are 
shown in Table III. At the beginning of the study, mono-
cyte cytokine release correlated with plasma hsCRP 
levels, and as there were correlations between hsCRP or 
cytokine release and HOMA-IR. Moreover, baseline lev-
els of hsCRP, TNF-a, and interleukin-6 correlated with 
age. Treatment-induced changes in cytokine release 
correlated with the impact of hypolipidaemic treatment 
on hsCRP The effect of fenofibrate and simvastatin/ 
/fenofibrate combination therapy on hsCRP, TNF-a, and 
interleukin-6 correlated with age. Moreover, in older 
adults there were correlations between the effects of 
fenofibrate and simvastatin/fenofibrate combination 
therapy on TNF-a and interleukin-6 release and hsCRP 
and on HOMA-IR. No other correlations were observed. 
Discussion
This study shows for the first time that age may par-
tially determine the effect of fenofibrate on cytokine 
release and low-grade inflammation. In line with this 
hypothesis, both fenofibrate alone and in combina-
tion with simvastatin reduced circulating levels of 
all cytokines measured in our study in patients aged 
between 51 and 75 years, while in the younger subjects 
its effect was limited to interleukin-1b and MCP-1. 
Moreover, the impact of fenofibrate on hsCRP was 
more pronounced in the former group of patients. In 
patients receiving combined hypolipidaemic therapy 
this effect cannot be explained by simultaneous use of 
a HMG-CoA reductase inhibitor because simvastatin 
alone reduced cytokine release and decreased hsCRP 
to a similar extent in both age populations. Taking into 
account the complex proatherogenic effect of TNF-a 
and interleukin-6 [4, 5], as well as the important role 
of monocytes/macrophages [25, 26] and low-grade in-
Table III. Correlations between the assessed variables
Tabela III. Korelacje pomiędzy ocenianymi markerami
Younger adults1 Older adults2
hsCRP TNF-a 0.55* (0.39*, 0.48*, 0.55*) 0.57* (0.48*, 0.46*, 0.59*)
hsCRP Interleukin-1b 0.38* (0.37*, 0.34*, 0.30*) 0.50* (0.39*, 0.42*, 0.51*)
hsCRP Interleukin-6 0.47* (0.52*, 0.53*, 0.56*) 0.42* (0.51*, 0.58*, 0.47*)
hsCRP MCP-1 0.35* (0.46*, 0.41*,0.47*) 0.37* (0.40*, 0.36*, 0.30*)
HOMA-IR hsCRP 0.43* (0.05, 0.18, 0.23) 0.50* (0.12, 0.46*, 0.53*)
HOMA-IR TNF-a 0.46* (0.11, 0.24, 0.21) 0.49* (0.16, 0.38*, 0.61*)
HOMA-IR Interleukin-1b 0.38* (0.08, 0.22, 0.19) 0.42* (0.02, 0.22, 0.18)
HOMA-IR Interleukin-6 0.40* (0.15, 0.20, 0.18) 0.43* (0.11, 0.59*, 0.34*)
HOMA-IR MCP-1 0.29* (0.13, 0.23,0,21) 0.31* (0.12, 0.17, 0.19)
All studied patients3
Age hsCRP 0.37* (0.11, 0.37*, 0.29*)
Age TNF-a 0.39* (0.14, 0.32*, 0.38*)
Age Interleukin-1b 0.21 (0.13, 0.19, 0.18)
Age Interleukin-6 0.34 (0.17, 0.38*, 0.37*)
Age MCP-1 0.20 (0.16, 0.20, 0.20)
Data represent the correlation coefficients (r values) at baseline and in parentheses after treatment with simvastatin, fenofibrate, and combination therapy.  
120–50 years old; 251–75 years old; 320–75 years old; *statistically significant
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flammation [6, 7] in atherogenesis, the obtained results 
may be relevant. They suggest that older adults may 
receive greater benefit from PPAR-a activator therapy 
than younger ones, while the potency of HMG-CoA 
reductase inhibitors does not depend on the age.
Baseline levels of hsCRP, as well as monocyte release 
of TNF-a and inteleukin-6, were higher in older than in 
younger adults. These differences cannot be associated 
with various clinical characteristics of the participants 
because sex distribution, smoking habit, and blood 
pressure were similar in younger and older adults. They 
cannot be also attributed to increased body weight and 
more pronounced dyslipidaemia, as a consequence 
of aging [31, 32], because potential participants were 
initially preselected in order to obtain weight- and 
plasma lipid-matched groups. Moreover, higher levels 
of TNF-a, interleukin-6, and hsCRP persisted even 
after adjusting for body mass index and lipids (data 
not shown). However, the obtained results are prob-
ably, at least in part, associated with impaired insulin 
receptor action because monocyte release of TNF-a, 
interleukin-6, as well as plasma hsCRP levels correlated 
with HOMA-IR. Interestingly, TNF-a is one of the 
factors responsible for insulin resistance [33, 34], while 
increased interleukin-6 levels may also contribute to its 
development [35, 36]. Apart from a causative role in the 
pathogenesis of insulin resistance, increased monocyte 
production of TNF-a and interleukin-6 may be induced 
by impaired insulin receptor action, thus leading to the 
development of a vicious circle that may contribute to 
increased morbidity and mortality in older adults.
Increased monocyte production of TNF-a and in-
terleukin-6 may contribute to elevated plasma levels of 
both cytokines, as observed previously by other authors 
in older adults [3]. The monocyte isolation procedure 
used in the study allowed us to obtain similar num-
bers of monocytes in both age populations. Therefore, 
the obtained results reflect differences in monocyte 
secretory function and cannot be explained by various 
numbers of these cells in peripheral blood taken from 
participants of our study. 
Previously [18] we did not observe any differences 
in monocyte cytokine release between the effect of 
statin/fibrate combination therapy and the effect of 
a statin and a fibrate administered alone in type 2 
diabetes patients with mixed dyslipidaemia treated 
with metformin. Although some participants of that 
study, fulfilling the criteria of mixed dyslipidaemia, 
were included in the present analysis there are some 
disparities between the results of the two studies. In 
the present study the strongest effect on TNF-a and 
interleukin-6 release was observed in older adults re-
ceiving the combination therapy, and the impact of this 
treatment option was stronger in older than in younger 
adults. These findings as well as the most pronounced 
effect on plasma lipids and on hsCRP suggest that 
older adults, particularly at high cardiovascular risk, 
may gain the greatest benefits from statin/fibrate com-
bination therapy. In turn, in the population under the 
age of 50 years, the benefits statin/fibrate combination 
therapy may be less pronounced.
Interestingly, unlike TNF-a and interleukin-6, 
treatment-induced changes in interleukin-1b and MCP-
1 release did not differ between patients belonging to 
both age populations, and were similar in extent in 
patients receiving statin/fibrate combination therapy 
and those receiving only one hypolipidaemic agent. 
This finding suggests that cellular signal pathways 
regulating monocyte secretion of various cytokines 
are partially distinct. Monocyte secretory function is 
modulated by many factors, influencing cytokine re-
lease both via direct and indirect mechanisms [37]. The 
net effect is a result of their mutual interactions, and 
this complex regulation seems to explain well the lack 
of parallel changes in the release of the investigated 
cytokines in our study. Interestingly, this explanation 
may also account for the finding that, contrary to TNF-a 
and interleukin-6, baseline release of interleukin-1b and 
MCP-1 did not depend on age.
The improvement in plasma lipids does not seem to 
play a role in reducing monocyte cytokine release by 
simvastatin, fenofibrate, and simvastatin/fenofibrate 
combination therapy in younger as well as in older 
adults with type 2 diabetes and atherogenic dyslipi-
daemia. However, the presence of correlations between 
the effects on cytokine release and on hsCRP shows 
that monocyte-suppressing effects of hypolipidaemic 
treatment options investigated in the present study 
contribute to their systemic anti-inflammatory effects, 
and partially explains the different hsCRP levels in both 
age populations.
Because this study was an observational one we can 
only hypothesise about the mechanisms responsible for 
the age-dependent effects of fenofibrate. They may re-
sult from changes in insulin sensitivity. In line with this 
hypothesis, the effect of simvastatin, having a neutral 
effect on glucose homeostasis, was unrelated to age. 
On the other hand, our findings may be explained by 
alterations in PPAR-a transmission. PPAR-a expression 
decreases with age, while PPAR-a downstream genes 
for some its key pathways, including nuclear factor-kB, 
activator protein-1 and signal transducers and activa-
tors of transcription, are up-regulated by aging [38]. 
Therefore, restoring normal PPAR-a signalling may be 
more important if this signalling is impaired, which 
takes place in older adults, than when intact.
This study has some limitations. The most important 
of them is a limited number of participants, as well as 
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a short treatment period, limiting the statistical signifi-
cance of the findings. Secondly, our results should be 
interpreted with caution because the study investigated 
only surrogate endpoints. Moreover, our study was 
only a retrospective analysis and its findings should be 
confirmed in larger trials with hard endpoints. Finally, 
the study protocol does not allow us to answer the 
question of whether a similar relationship between 
the age and the strength of hypolipidaemic therapy is 
observed in patients not suffering from diabetes and 
not receiving metformin. 
Conclusions
The results of the study indicate that the effect of fenofi-
brate and simvastatin/fenofibrate combination therapy 
on proinflammatory cytokine release and low-grade 
systemic inflammation is more pronounced in older 
than in younger adults. They indicate that age may par-
tially determine monocyte-suppressing and systemic 
anti-inflammatory effects of fibrates, suggesting that 
older adults may benefit more from fibrate and statin/ 
/fibrate combination therapy.
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